Downloads
192
Article Figures & Data
Figures
- Figure Trainees' Average Comfort Levels Across All Topics Improved After the Seminar Series: (A) All Trainees, (B) First-Year Fellows Only, and (C) Second-Year (and Beyond) Fellows Only
Tables
Percentage of respondents to precourse survey (n = 72) Percentage of respondents to postcourse survey (n = 26) Level of training Resident 18.1 11.5 First-year fellow 56.9 53.8 Second-year (or beyond) fellow 25.0 34.6 No. of trainees at respondent's institution 1 27.1 23.0 2 20.3 19.2 4 22.0 19.2 4 or more 30.5 38.4 Geographic location of training program Northeast United States 39.0 42.3 Southeast United States 5.1 3.8 Midwest United States 27.1 19.2 Southwest United States 11.9 3.8 West United States 16.9 30.8 Topic Preseries-weighted average of trainee comfort level (n = 72, scale 1–5) Postseries-weighted average of trainee comfort level (n = 26, scale 1–5) Preseries-weighted average of program director expected value (n = 22, scale 1–5) Postseries-weighted average of program director impression of educational value (n = 12, scale 1–5) Advanced MRI techniques for MS/neuroinflammation 2.74 3.77 4.55 4.2 Anti-NMDA receptor encephalitis and mechanisms of disease 3.38 4.12 4.59 4.45 Autoimmune myelitis and its mimics 3.32 4.12 4.77 4.55 B-cell and autoantibody-mediated pathogenesis in CNS autoimmunity 3.09 4.0 4.82 4.36 Basic science of remyelination 2.53 3.58 4.36 4.1 Clinical trial design 2.55 3.42 4.75 4.27 Emerging autoimmune diseases 2.88 3.85 4.73 4.6 Ethnicity and diversity in the MS experience 2.92 3.81 4.41 4.45 Hematopoietic and mesenchymal stem-cell therapy for MS 2.31 3.54 4.43 4.09 Immunobiology of MS 2.93 3.85 4.82 4.44 Integrative medicine and cannabis 2.54 3.42 4.18 3.6 Lab techniques and tools for understanding antibody-mediated diseases 2.61 3.65 4.5 4.45 Neurorheumatology: Neurosarcoidosis, CNS vasculitis, CNS lupus, neuro-Beçhet's 2.78 3.84 4.82 4.64 Pediatric MS 2.74 3.73 4.55 4.4 PML and opportunistic infections 3.12 3.96 4.55 4.5 Progressive MS: challenges in finding and demonstrating effective therapies 3.2 4.12 4.73 4.42 Symptomatic management of advanced MS 3.53 4.27 4.64 3.8 Urological issues and their management in MS 2.61 3.73 4.41 4.4 Abbreviations: MS = multiple sclerosis; PML = progressive multifocal leukoencephalopathy.
Theme Example quotes Benefits of interactions with leading experts The lectures are fantastic and it is great to hear from the speakers themselves. Excited to be able to participate myself. Improvement on prior approaches for learning niche and cross-disciplinary topics Wonderful seminar series. Love the concept of topics that may not be core topics at each institution or universal. Overall, I thought the series was very useful, particularly in covering topics other than MS DMTs. Opportunities for live and asynchronous participation This was an excellent resource during the MS fellowship, especially the on-demand videos which could be watched at a later time. Areas for growth Allow more time for discussion—many sessions went over time and it would be great to allow for more engagement. Abbreviations: DMT = disease-modifying therapy; MS = multiple sclerosis.
Name Location Contribution John Peters, MD Department of Neurology, Yale School of Medicine, New Haven, CT Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data Jeffrey A. Cohen, MD Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, OH Drafting/revision of the manuscript for content, including medical writing for content; study concept or design John R. Corboy, MD, MA Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver Drafting/revision of the manuscript for content, including medical writing for content; study concept or design Sarah E. Hopkins, MS, MSPH Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania Drafting/revision of the manuscript for content, including medical writing for content; study concept or design Le H. Hua, MD Mellen Program for Multiple Sclerosis, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV Drafting/revision of the manuscript for content, including medical writing for content; study concept or design Mihir Kakara, MBBS Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia Drafting/revision of the manuscript for content, including medical writing for content Derek McFaul, DO Department of Neurology, Oregon Health & Science University, Portland Drafting/revision of the manuscript for content, including medical writing for content Ahmed Z. Obeidat, MD, PhD Department of Neurology, Medical College of Wisconsin, Milwaukee Drafting/revision of the manuscript for content, including medical writing for content; study concept or design Vijayshree Yadav, MD, MCR Department of Neurology, Oregon Health & Science University, Portland Drafting/revision of the manuscript for content, including medical writing for content; study concept or design Erin E. Longbrake, MD, PhD Department of Neurology, Yale School of Medicine, New Haven, CT Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
